The Point Prevalence Program (PPP) is a collaborative project between Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the Critical Care Division of The George Institute. Aim As a coordinated and validated project , the Point Prevalence Program provides  infrastructure to conduct several multi-centre observational studies simultaneously on specified study days each year. The impetus for the PPP is to improve the efficiency of the collection of observational data that helps design clinical trial protocols for future ANZICS CTG studies. A further use of the PPP is that it can help with generating data to understand how research findings are translated into clinical practice. Significance The program facilitates collaborations amongst members of the CTG with an average of 44 ICUs participating each study day from a range of tertiary, metropolitan, regional-rural and private hospitals with an average recruitment per study day of more than 550 participants.

Hyperglycaemia is a common finding in patients who are acutely ill even in the absence of a prior diagnosis of diabetes mellitus. In acutely ill patients, hyperglycaemia is associated with a worse outcome. As hyperglycaemia is consistently associated with increased morbidity and mortality, critical care researchers have conducted a number of trials to investigate whether tighter control of blood glucose in critically ill patients is beneficial. To date there have been over 30 randomised controlled trials of tight glucose control in critical care settings. However, many studies have reported non-significant results; in part this is because many of the trials were small and when considered alone had insufficient statistical power to examine the effects of tight glucose control on mortality. Aims The aim of this collaborative research project is to combine the individual patient data from all randomized controlled trials of tight glucose control in critically ill adults around the world to conduct

Project aims to develop an integrated, patient-centred, affordable and sustainable system for proactive management of patients undergoing peritoneal dialysis based on patients’ needs using innovative technologies and methodologies for service design Methods This is an observational cohort study which aims to develop a user-friendly and functional IT supported system for education and monitoring of patients undergoing peritoneal dialysis in their homes. We intend to collect information on physiological measures through different sensors in order to be able to compare and ascertain which methods are most acceptable to patients and providers. Study sites Postgraduate Institute of Medical Education and Research, Chandigarh and Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Current status The prototype Mobile Application is being tested

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 15.0px Times; color: #323333; -webkit-text-stroke: #323333} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 18.0px Arial; color: #323333; -webkit-text-stroke: #323333} span.s1 {font-kerning: none} span.s2 {text-decoration: underline ; font-kerning: none; color: #772583; -webkit-text-stroke: 0px #772583} span.s3 {font: 14.0px Calibri; font-kerning: none; color: #000000; -webkit-text-stroke: 0px #000000} span.s4 {font: 13.0px Calibri; font-kerning: none} span.s5 {font: 9.0px 'Times New Roman'; font-kerning: none} Fluid administration is a fundamental component of the management of critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by evidence that suggests its high chloride content may have clinically important adverse effects. Two pivotal George Institute trials, the Saline versus Albumin

A prospective, multicentre, parallel group, concealed, blinded, randomised controlled trial in critically ill mechanically-ventilated adults. The aim is: To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is non-inferior to standard practice (daily administration of pantoprazole 40 mg IV) when judged by the incidence of clinically important gastrointestinal (GI) bleeding?  To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is superior to standard practice (daily administration of pantoprazole 40 mg IV) as it results in a reduction in net harm by reducing the incidence of serious infectious complications (ventilator-associated pneumonia and Clostridium difficile infection) and therefore "downstream" harms when measured as duration of mechanical ventilation, intensive care unit (ICU) and hospital length of stay, and 90-day mortality? 

Chronic kidney disease (CKD) has become a growing public health problem worldwide with a serious socio-economic impact. CKD results in mortality due to progression to end-stage renal disease and a disproportionate increase in the risk of cardiovascular disease (CVD) and associated deaths. Recent advances suggest the possibility of using biologically relevant biomarkers to develop prediction algorithms for outcomes in patients with CKD. However, there are no large longitudinal studies comparing the differences in racially, geographically and genetically different populations. Aim: Project aims to establish a large cohort of Indian patients with moderate kidney failure (40-60% reduction in kidney function) by enrolling 5000 patients cared for at 8 centers nationwide, who will be prospectively followed for a minimum of five years and to develop prediction algorithms. It will be the first study to evaluate the prediction power of biologically important biomarkers on clinically relevant end